HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions
- 4 January 2016
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 126 (1), 5-11
- https://doi.org/10.1172/jci85446
Abstract
Identification of HPV infection as the etiologic agent of virtually all cases of cervical cancer, as well as a proportion of other epithelial cancers, has led to development of three FDA-approved multivalent prophylactic HPV vaccines composed of virus-like particles (VLPs). This essay describes the research and development that led to the VLP vaccines; discusses their safety, efficacy, and short-term effect on HPV-associated disease; and speculates that even a single dose of these vaccines, when given to adolescents, might be able to confer long-term protection. The HPV field exemplifies how long-term funding for basic research has lead to clinical interventions with the long-term potential to eradicate most cancers attributable to HPV infection. Although this essay is the result of my receiving the 2015 Harrington Prize for Innovation in Medicine from the Harrington Discovery Institute and the American Society for Clinical Investigation, this clinical advance has depended on the research of many investigators, development of commercial vaccines by the pharmaceutical companies, and participation of many patient volunteers in the clinical trials.Keywords
This publication has 44 references indexed in Scilit:
- Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010The Journal of Infectious Diseases, 2013
- A Review of Clinical Trials of Human Papillomavirus Prophylactic VaccinesVaccine, 2012
- Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 VaccineJNCI Journal of the National Cancer Institute, 2011
- In Vivo Mechanisms of Vaccine-Induced Protection against HPV InfectionCell Host & Microbe, 2010
- The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface bindingProceedings of the National Academy of Sciences of the United States of America, 2009
- Papillomaviruses in the causation of human cancers — a brief historical accountVirology, 2009
- Cancer risk in people infected with human immunodeficiency virus in the United StatesInternational Journal of Cancer, 2008
- Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human seraJournal of General Virology, 1994
- Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNANature, 1987
- Identification of the Protein Encoded by the E6 Transforming Gene of Bovine PapillomavirusScience, 1985